Ormrod D J, Cawley S, Miller T E
Chemioterapia. 1985 Aug;4(4):313-23.
Few immunomodulators are available for the control of infectious disease. One reason has been the lack of a suitable protocol for evaluating such agents. We have presented a series of assays of immune function that will allow a standardized approach to this problem. The value of this protocol has been established using long-term low dose, and short-term high dose, administration of bestatin, a small molecular weight microbial product. The experiments were done using both normal and immunocompromised animals. Bestatin had no effect on circulating leukocytes or the reticuloendothelial system. Leukocyte mobilization and T cell responsiveness in immunocompromised animals were enhanced following bestatin treatment. The antibody response to SRBC doubled in normal animals while the same treatment schedule resulted in a marked reduction in the response to Escherichia coli lipopolysaccharide. These results have established the value of the protocol and identified some new immunomodulating properties of bestatin which may be useful in the control of infectious disease.
可用于控制传染病的免疫调节剂很少。原因之一是缺乏评估此类药物的合适方案。我们提出了一系列免疫功能测定方法，将为解决这个问题提供标准化方法。通过长期低剂量和短期高剂量施用小分子微生物产物贝司他汀，已确定了该方案的价值。实验使用正常动物和免疫受损动物进行。贝司他汀对循环白细胞或网状内皮系统没有影响。贝司他汀治疗后，免疫受损动物的白细胞动员和T细胞反应性增强。正常动物对SRBC的抗体反应增加了一倍，而相同的治疗方案导致对大肠杆菌脂多糖的反应明显降低。这些结果确定了该方案的价值，并确定了贝司他汀的一些新的免疫调节特性，这些特性可能有助于控制传染病。
